Michael S. Weiss, the Company’s Chairman and Chief Executive Officer stated, “The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are excited to ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

TG Therapeutics Inc (TGTX) reports over 230% year-over-year revenue growth, raises full-year guidance, and outlines future ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Raising BRIUMVI U.S. net product revenue target to $300 to $305 million for the full year 2024, prior guidance of $290 to $300 million for full ...

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with ...

We recently compiled a list of the 10 Stocks Set to Explode in 2025. In this article, we are going to take a look at where TG ...

TD Cowen analyst Tara Bancroft maintained a Buy rating on TG Therapeutics (TGTX – Research Report) today and set a price target of ...

Futures on the Dow Jones Industrial Average (DJI) are down 182 points at last check this morning, while futures tied to the ...